Hepatitis C Prevalence Among Filipino Blood Donors
Among Filipino blood donors, hepatitis C (HCV) seroprevalence is approximately 0.48%, with significantly higher rates in male donors, replacement donors, first-time donors, and those aged 25-44 years old 1.
Specific Prevalence Data for Filipino Blood Donors
A comprehensive 5-year retrospective study (2013-2017) from Region 3, Philippines, provides the most relevant data for your question 1:
- Overall HCV seroprevalence: 0.48% across all blood donors
- Age distribution: The 25-44 year age group showed the highest rates of reactive donors (note: your question asks about 45+ years, but the data shows peak prevalence in the younger 25-44 cohort)
- Sex distribution: Male donors demonstrated higher HCV seroprevalence compared to females
- Donor category: Replacement donors had higher rates than voluntary donors
- Donation history: First-time donors showed higher seroprevalence than repeat donors
An earlier study (2002-2004) corroborates these findings, reporting HCV prevalence of 0.3% among hospital-based blood donors in the Philippines 2. This study also confirmed that males were at increased risk for HCV infection.
Key Clinical Implications
The data shows a reassuring downward trend - the overall seroprevalence of transfusion-transmissible infections decreased from 2013 to 2017, indicating improving blood safety in the Philippines 1.
High-Risk Donor Profiles to Monitor:
- Male donors (consistently higher risk across studies)
- Replacement donors (higher than voluntary donors)
- First-time donors (versus repeat donors)
- Age 25-44 years (peak prevalence group, not 45+)
Important Caveat:
The question specifically asks about donors aged 45 years or older, but the available Philippine data actually shows the highest prevalence in the 25-44 year age group, not in older donors 1. This is an important distinction for screening and counseling purposes.
Screening Recommendations Context
While the provided guidelines focus on U.S. populations 3, the principle of universal screening for adults aged 18-79 years aligns with identifying HCV in blood donor populations. All blood donors should undergo mandatory HCV screening regardless of risk factors 4.
Donors with repeatedly reactive anti-HCV results must be indefinitely deferred from blood donation for transfusion products and should receive confirmatory testing with supplemental assays and referral for clinical evaluation 4.